Announced Date: 2025-04-23 (April 23, 2025)
Asset Name: QX030N
Licensor (Seller): Qyuns Therapeutics (China)
Licensee (Buyer): Caldera Therapeutics (US, NewCo)
.
Asset Modality: Bispecific antibody (BsAb)
Asset Target: undisclosed
Potential Indication: immunologic disorders
Current Stage: pre-clinical stage
.
Scope of Authority:
Qyuns Therapeutics grants Caldera Therapeutics an exclusive right to develop and commercialize QX030N globally.
Caldera Therapeutics is granted an exclusive, royalty-bearing, transferable, sublicensable right to research, develop, register, manufacture and commercialize QX030N worldwide.
.
Payment Detail:
Qyuns Therapeutics will receive:
(i) upfront payment of USD$10 million,
(ii) receive approximately 24.88% of the equity interest in Caldera Therapeutics.
(iii) additional payments of up to USD$545 million, subject to the achievement of certain clinical development, regulatory and commercial milestones.
(iv) tiered royalties on net sales from Caldera Therapeutics during a specified time period after the first
commercial sales of QX030N.
.
Link:
2025042400007.pdf (hkexnews.hk)
.
Note:
Chinese Name of Qyuns Therapeutics, 荃信生物
